Nanomaterials and Nanoparticles in Biomedical Applications and Immunotherapy

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1794

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium
Interests: biological applications of nanomaterials; light-sensitive nanomaterials; nano- biotechnology; cell biology and cell death; biomaterials; hybrid and composite materials; microscopy; SERS; layer-by-layer; hydrogels; capsules; encapsulation; enzymes; calcium carbonate; drug delivery; environmental protection

Special Issue Information

Dear Colleagues,

Biomaterials comprised of nanoparticles and nanomaterials are finding an increased number of applications in various fields, particularly in biomedicine, where drug delivery carriers are actively sought. In this field, immunotherapy and personalized medicine represent some of the fastest growing areas. To develop new treatments, a detailed understanding of immunogenic cell death is essential.

The Special Issue on “Nanomaterials and Nanoparticles in Biomedical Applications and Immunotherapy” focuses on novel concepts and developments across a broad range of biomedical and immunotherapy applications. To further stipulate developments in these areas, nanoparticles and nanomaterials are identified as the key components in further transferring and promoting developments in these biomedical areas.

A clear interdisciplinary and multidisciplinary research line unifies I. Biomedical and II. Biomaterial research scopes.    

Prof. Dr. Andre G. Skirtach
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomedical scope
    • biomedicine, immunology
    • immunogenic cell death
    • immunotherapy, personalized medicine
    • apoptosis, necroptosis, pyroptosis, ferroptosis
    • osteointegration, bones
  • biomaterial scope
    • pharmacology, drug delivery
    • silica, mesoporous silica
    • calcium carbonate, calcium phosphate
    • polymeric carriers, hydrogels, dendrimers
    • lipid-based, micelles, liposomes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3284 KiB  
Article
Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation
by Adil Ali Sayyed, Piyush Gondaliya, Irene K. Yan, James Carrington, Julia Driscoll, Anuradha Moirangthem and Tushar Patel
Nanomaterials 2023, 13(20), 2751; https://doi.org/10.3390/nano13202751 - 12 Oct 2023
Cited by 3 | Viewed by 1558
Abstract
Extracellular vesicles (EVs) show promise for targeted drug delivery but face production challenges with low yields. Cell-derived nanovesicles (CDNVs) made by reconstituting cell membranes could serve as EV substitutes. In this study, CDNVs were generated from mesenchymal stem cells by extrusion. Their proteomic [...] Read more.
Extracellular vesicles (EVs) show promise for targeted drug delivery but face production challenges with low yields. Cell-derived nanovesicles (CDNVs) made by reconstituting cell membranes could serve as EV substitutes. In this study, CDNVs were generated from mesenchymal stem cells by extrusion. Their proteomic composition, in vitro and in vivo toxicity, and capacity for loading RNA or proteins were assessed. Compared with EVs, CDNVs were produced at higher yields, were comprised of a broader range of proteins, and showed no detrimental effects on cell proliferation, DNA damage, or nitric oxide production in vitro or on developmental toxicity in vivo. CDNVs could be efficiently loaded with RNA and engineered to modify surface proteins. The feasibility of generating immunomodulatory CDNVs was demonstrated by preparing CDNVs with enhanced surface expression of PD1, which could bind to PD-L1 expressing tumor cells, enhance NK and T cell degranulation, and increase immune-mediated tumor cell death. These findings demonstrate the adaptability and therapeutic promise of CDNVs as promising substitutes for natural EVs that can be engineered to enhance immunomodulation. Full article
Show Figures

Graphical abstract

Back to TopTop